Prostate cancer care has evolved, but challenges and unmet needs remain. This #Movember, we’re highlighting the need for further innovation in advanced prostate cancer care, where today’s options are not enough. At Novartis, we are working with world-class scientists to uncover new possibilities in prostate cancer care. #ProstateCancerAwareness
Info
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
- Website
-
http://www.novartis.com
Externer Link zu Novartis
- Branche
- Arzneimittelherstellung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Basel, Baselstadt
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Spezialgebiete
- Cardiovascular, Immunology, Neuroscience, Solid Tumors, Hematology, Chemistry, xRNA, Radioligand und Gene and cell therapy
Orte
Beschäftigte von Novartis
-
David Yee
Head Portfolio Systems & Capabilities, Enterprise Portfolio Insights, Strategy & Growth at Novartis
-
Rodolfo Garcia de Alba Cassaigne
Regional Category Procurement Director, US Marketing Agencies
-
Kelley Dallas Priddy, M.S.
Medical Sales Specialist | Award Winner | Drives Sales Performance Through Analytics & Business Planning
-
Jennifer Ma
Updates
-
At our Meet Novartis Management event for investors and analysts today in London, we announced that we rolled forward mid-term guidance and highlighted our robust pipeline to drive sustainable growth. With a strong portfolio, we upgraded sales guidance for key growth drivers, expect 15+ potential submission-enabling readouts over the next two years and have more than 30 high-value medicines in our pipeline. Learn more about our outlook here: https://lnkd.in/gqrffTgH #NovartisNews $NVS $NOVN #ReimaginingMedicine
-
“You realize… the power is with us.” At One Young World 2025, 40 Novartis emerging leaders joined a global community of changemakers to share ideas and build connections that will drive impact far beyond this summit. Our delegates arrived as scientists, clinicians, data strategists, and advocates. They left as a chorus of purpose-driven voices ready to shape what’s possible for patients, communities, and the planet. Change begins with vision, and we’re committed to helping tomorrow’s leaders bring it to life. Watch the wrap-up video to hear their reflections and see what inspired them at OYW. #NovartisatOYW
-
This #Movember, we’re raising awareness of prostate cancer and the need for more innovation in advanced stages of disease, where today’s treatment options are limited. Prostate cancer remains a significant global health challenge as the most frequently diagnosed cancer in men in more than half the world. Care has evolved in the past 20 years with new technologies to diagnose and treat patients with prostate cancer and help them live longer. However, there is more to do. Learn more: https://lnkd.in/g9V46Jd6 #ProstateCancerAwareness
-
Want to know the one thing that drives every breakthrough we’ve made? We’ll give you a hint: it’s not technology. While some factors, such as investment in systems and R&D are essential, our leaders know there's another key ingredient. Fiona H. Marshall, our President of Biomedical Research, shares our secret to success and why it’s so important to us. https://lnkd.in/gyMjFJ44 #Novartis #NovartisScience #BiomedicalResearch #ThriveTogether
-
Could this be the next big innovation in malaria treatment? We are excited to announce positive Phase III data for a next-generation antimalarial candidate with the potential to treat the disease, fight drug-resistant parasites, and block transmission. Born in our labs in San Diego and developed with the help of our partners, it contains a novel ingredient which was identified after screening more than 2.3 million compounds. If approved by regulatory authorities, this innovation could mark a step forward in the fight against malaria. Medicines for Malaria Venture | European & Developing Countries Clinical Trials Partnership (EDCTP) | WANECAM
-
Today we celebrate the opening of our new US manufacturing facility - a key milestone in our continued investment to reimagine how innovation reaches patients across the US.
Today, we are announcing the opening of a new state-of-the-art radioligand therapy (RLT) manufacturing facility in Carlsbad, California. Representing a key milestone in our $23 billion US expansion plan over the next five years, the opening of our third RLT site allows us to meet future demand, continue on-time delivery to patients across the western US, and augments our world-class supply chain capabilities. By reimagining how innovation reaches patients, this opening reflects our strong investment in the US and our commitment to bringing this pioneering treatment to more patients across the country. 🔗 Discover how: https://lnkd.in/dxDQVCra #NovartisUS #ReimaginingMedicine
-
Big ideas start with bold voices, and ours are ready to make an impact! We’re proud to share that 40 emerging Novartis leaders are heading to One Young World 2025 in Munich! These passionate changemakers will join thousands of peers from over 190 countries to tackle some of the world’s most pressing challenges— from health equity to sustainability—through bold, human-led action. Each brings a unique perspective, reinforcing our unwavering commitment to improving human health and unlocking the power of science with integrity and heart. By investing in early career leaders, we invest in the future of healthcare. Follow along to experience #OYW25 through their eyes and see how the future isn’t something we wait for, it’s something we build. Together. #NovartisatOYW
-
-
It’s worryingly easy to fall into the trap of thinking: “It will never happen to me.” Yet, 1 in 8 women will be diagnosed with breast cancer in their lifetime.¹ This Breast Cancer Awareness Month, we are proud to spotlight Iris Zemzoum MD, MBA, President Europe at Novartis, alongside footballers Jen Beattie MBE, and Kenza Dali, who respectively share their clinical expertise and personal stories in ELLE Magazine to remind us of the importance of early and empowered action in breast health. While early detection plays a vital role in improving health outcomes, it’s also important for those impacted by early breast cancer to stay proactive in speaking with their doctor about actions they can take to increase their chances of a cancer-free future. Let’s inspire women everywhere to feel confident, informed, and empowered in being proactive about their breast health. Read more: https://lnkd.in/gmfBrywQ #BreastCancerAwarenessMonth #BCAM #BreastCancer Reference: 1. International Agency for Research on Cancer (IARC). Available from: https://lnkd.in/gMbXxetY Accessed October 2025
-
We are proud of our legacy of innovation in immunology and rheumatology — and today at #ACR25, we’re excited to share new data on Sjögren’s disease. Sjögren’s is a heterogeneous, systemic disease with no approved targeted treatments. Symptoms, such as persistent dryness, fatigue, and pain, can significantly impact physical, mental and social well-being. Beyond these symptoms, Sjögren’s can affect multiple organs and systems. That’s why we're focused on addressing the need for patient-centered care — to address the full physical and emotional burden of Sjögren’s.
Verbundene Seiten
Ähnliche Seiten
Finanzierung
Novartis
Insgesamt 2 Finanzierungsrunden
Weitere Informationen auf Crunchbase
Letzte Runde
Fremdkapital nach Börsengang
Externer Crunchbase-Link für die letzte Finanzierungsrunde
2.487.694.394,00 $